Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
901-920 of 936 trials

New Treatment for Patients with XXX Cancer

We are exploring a new combination therapy for people with XXX cancer who need a second-line treatment. The goal is to see if this approach is safer and more effective than standard care.

Cancer Eligible for Second-Line Treatment1-2 yearsSafety phase (I)Oncology

EGL-003 for Autoimmune Diseases

We are testing a new treatment called EGL-003 to see how safe it is and how the body handles it. The study starts with healthy volunteers and then includes adults with autoimmune diseases.

Atopic Dermatitis1-2 yearsSafety phase (I)DermatologyRheumatology

NTX-1955: Effects on Brain Function

We are examining how the oral medication NTX-1955 affects the brain in healthy adults. This study aims to gather insights that could inform future treatments.

Generalized Anxiety Disorder6-12 monthsSafety phase (I)Psychiatry

Familial Polycythemia: New Drug Treatment Study

We are testing a new drug for individuals with familial polycythemia caused by an EPO gene mutation. The goal is to see if it is safe and effective in managing their condition.

Familial Polycythemia with EPO Gene Mutation1-2 yearsSafety phase (I)Hematology

Testing CLE-905-AG for Safety and Tolerability

We are studying a new medication to see how safe it is and how the body handles it in healthy individuals. This trial will also explore its effects when combined with another drug.

Schizophrenia6-12 monthsSafety phase (I)Psychiatry

LY3537031 for Liver Function Study

We are investigating how LY3537031 affects people with normal liver function and those with mild to severe liver impairment. This study aims to learn more about its safety and effectiveness in different liver health conditions.

Healthy Participants6-12 monthsSafety phase (I)HepatologyInternal Medicine

Dilated Cardiomyopathy: AZD4063 Study

We are investigating the safety and effects of AZD4063 in adults with dilated cardiomyopathy due to a specific PLN gene mutation. The study aims to see how the drug works in the body and its impact on PLN mRNA levels.

Dilated Cardiomyopathy>2 yearsSafety phase (I)CardiologyInternal Medicine

Deuruxolitinib: Safety Study in Healthy Adults

We are testing a new medication to see how safe it is and how the body reacts to it in healthy adults. This study helps us understand its potential for future treatments.

Alopecia Areata6-12 monthsSafety phase (I)AllergologyInfectious DiseasesRheumatology

MK-4082: A Study in Healthy Volunteers

We are testing a new medication called MK-4082 in healthy individuals. This study aims to understand its safety and how it works in the body.

Weight Management3-6 monthsSafety phase (I)EndocrinologyInternal Medicine

Cold-Induced Urticaria: GTX-B001 Treatment

We are testing a new treatment for people with cold-induced urticaria to see how well it is tolerated and its effects on symptoms. The study includes both healthy volunteers and patients.

Cold-Induced Urticaria1-2 yearsSafety phase (I)AllergologyDermatology

RO7504109: Immune Cell Study

We are investigating how the new treatment RO7504109 affects immune cells in healthy individuals. This research may help us learn more about its potential uses in the future.

Healthy Participants6-12 monthsSafety phase (I)AllergologyDermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

Skin Immune Response: SYX-5219 Treatment

We are investigating how SYX-5219 affects immune responses in the skin. This study aims to understand its potential benefits for skin-related conditions.

Atopic Dermatitis3-6 monthsSafety phase (I)Dermatology

NTX-1955: CO2 Challenge Study

We are testing a new treatment called NTX-1955 in healthy participants to see how it affects carbon dioxide levels in the body. This research may help us understand its potential uses in health.

Generalized Anxiety Disorder1-2 yearsSafety phase (I)Psychiatry

ACD856: Safety Study in Healthy Volunteers

We are testing a new medication called ACD856 to see how safe it is and how it affects the body. This study involves healthy participants to help us understand its effects better.

DepressionCognitive DysfunctionAlzheimer’s Disease3-6 monthsSafety phase (I)NeurologyPsychiatry

Cenerimod: Bioavailability Study in Healthy Men

We are evaluating how well the body absorbs cenerimod in healthy male participants. This study aims to gather important information for future treatments.

Healthy Participants3-6 monthsSafety phase (I)

Survodutide: Comparing Two Formulations

We are studying how two different formulations of survodutide are absorbed by healthy people. This research may help improve future treatments using this medication.

Healthy Volunteers6-12 monthsSafety phase (I)

Drug Interaction Study: Carbamazepine and PF-07248144

We are investigating how multiple doses of Carbamazepine affect the way the body processes another medication, PF-07248144. This study aims to improve our understanding of drug interactions.

Locally Advanced or Metastatic ER+/HER2- Breast Cancer3-6 monthsSafety phase (I)Internal MedicineOncology

Psoriasis Treatment: CKD-704 vs. Skyrizi®

We are comparing a new biosimilar treatment for psoriasis with the approved Skyrizi® to see how safe it is and how well it works in healthy adults.

Moderately to Severely Active Crohn’s DiseaseModerate-to-Severe Plaque PsoriasisActive Psoriatic Arthritis6-12 monthsSafety phase (I)DermatologyGastroenterologyInfectious DiseasesRheumatology

Alzheimer’s Disease: MTX46943 Study

We are investigating a new compound to see if it is safe and effective for treating Alzheimer’s disease and other neurological disorders. This study looks at how the drug is absorbed and processed in the body.

Alzheimer's Disease6-12 monthsSafety phase (I)Internal MedicineNeurology

Pain Measurement: Nefopam and Oxycodone Study

We are exploring new test methods to measure pain in individuals using nefopam and oxycodone. This research aims to improve how we assess pain relief with these medications.

Chronic Pain6-12 monthsSafety phase (I)Internal MedicineNeurology